InvestorsHub Logo
Followers 27
Posts 1014
Boards Moderated 0
Alias Born 08/19/2016

Re: None

Monday, 04/03/2017 9:29:39 AM

Monday, April 03, 2017 9:29:39 AM

Post# of 403047
Interesting.....
Looks like BP wants to see what Kevetrin can do mono then what a 2nd drug will do......But what drug or drugs?


Cellceutix has initiated a Phase 2a trial of Kevetrin in platinum-resistant/refractory ovarian cancer. Patients will receive more frequent Kevetrin administration (3 times per week), escalating to higher dosing in the second cohort, and after trial completion will receive standard of care treatment
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News